Skip to main content

CBOT/CME Merger: An Arithmetical Subplot

I've been thinking again, for no very compelling reason, about the merger of the two great Chicago exchanges in 2007. In form, it was an acquisition of the Chicago Board of Trade by the Chicago Mercantile Exchange, after the CME won a bidding war with the Intercontinental Exchange (ICE),

I'm looking at Erika Olson's book about the behind-the-scenes maneuvering that ended in that result. One of the many subplots involves ERPs, the "exercise right privileges" possessed by many CBOT members with regard to yet another Chicago institution, the Chicago Board Options Exchange.
This takes some explaining. First, neither the CBOT nor the CBOE is a mere set of initials. Each is a true acronym, "see-bot" and "see-bow" respectively. Second, the CBOE, established in 1973, does what the name implies. It provides a forum for the trade in options. It was initially a spin-off from the CBOT, and they had a close continuing relationship. One part of that: everyone with at least 27,338 shares in the CBOT had the privilege of trading on the CBOE, an ERP.

Once a CME bid was announced, even before ICE became involved, the question arose: what happens to the ERPs?

The CEO of CBOT, Bernie Dan, was all in favor of the deal with CME. At one critical meeting, he explained to the members that every share of their equity in the exchange was going to be worth .3006 shares (that is, a little less than one third of a share) of the new entity, called The CME Group. So: how many shares of The CME Group would one need to qualify for an ERP? That is a straightforward mathematical question, what is .3006 of 27,338?

Well, straightforward in that one can easily enter it into a calculator. Personally I wouldn't want to try to do that in my head: !

Apparently, at the meeting when Dan announced the .3006-to-1 ratio, one of the members/traders did try to do it in his head.

As Olson writes, he "attempted to figure the numbers out loud and got it totally wrong." She gives the impression that she's doing him a solid by not naming him and subjecting him to innumeracy-shaming. "I heard other traders grumble in disapproval of the colleague's inability ... 'This is fucking embarrassing."

Really? Whoever he is, he need fear no disapproval from me. I admire anyone who would TRY to do that off the cuff sans calculator.

The answer, by the way, is that 8,217.8028 shares of CME stock were necessary to keep an ERP in the CBOE.

But I bet my bright readers have already figured that out.


Popular posts from this blog

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Francesco Orsi

I thought briefly that I had found a contemporary philosopher whose views on ethics and meta-ethics checked all four key boxes. An ally all down the line.

The four, as regular readers of this blog may remember, are: cognitivism, intuitionism, consequentialism, pluralism. These represent the views that, respectively: some ethical judgments constitute knowledge; one important source for this knowledge consists of quasi-sensory non-inferential primary recognitions ("intuitions"); the right is logically dependent upon the good; and there exists an irreducible plurality of good.

Francesco Orsi seemed to believe all of these propositions. Here's his website and a link to one relevant paper:

What was better: Orsi is a young man. Born in 1980. A damned child! Has no memories of the age of disco!

So I emailed him asking if I was right that he believed all of those things. His answer: three out of …